93 BRCA1 and 28 BRCA2 carriers received 1st-line chemotherapy (mainly anthracycline-based or CMF (CMF-like)) for the treatment of metastatic disease. Sporadic cases (n = 121) were used as a control. Marginally improved outcomes in BRCA1 carriers: OR: 66% vs. 50%; median PFS: 7.6 vs. 6.7 months; median OS: 15.0 vs. 13.6 months; significantly improved outcomes in BRCA2 carriers: OR: 89% vs. 50%; median PFS: 11.4 vs. 6.7 months; median OS: 19.3 vs. 13.6 months. The gene discussed is BRCA1; the disease is metastatic neoplasm.